Finnish-French molecular diagnostics company Mobidiag Oy is to be acquired by Hologic, Inc., a global leader in women’s health, for approximately €668 million. The transaction will accelerate global growth of Mobidiag’s platforms.

Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.“We are very excited to join Hologic’s diagnostic business,” said Tuomas Tenkanen, Mobidiag’s Chief Executive Officer. “Under the Hologic umbrella our business will continue to be committed to its existing customer base in Europe, including our home markets of Finland, France, Sweden and UK, however, Hologic’s commercial expertise, scale and investment strength, will accelerate the broader market adoption of our products. In addition, Hologic’s established U.S. regulatory and market development capabilities will rapidly facilitate the introduction of our products and maximize their potential in the United States.””Mobidiag’s operations will continue their growth based in Espoo, Finland,” said Tenkanen to Helsingin Sanomat.Mobidiag’s acquisition is one of the biggest aqcuisitions of Finnish growth companies by international companies by far.Before the aqcuisition, one of the biggest owners of Mobidiag is the University of Helsinki. The University made its first investment in Mobidiag already in 2006, so the company is a prime example of the University’s long-term investment in research-based startups.Photo: Pasi Hornamo/Espoo
Health Capital Helsinki